Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Eli Lilly And Co (LLY) Taltz Has A Higher Response Rate Than Stelara For Psoriasis

Detailed results from the IXORA-S study have revealed that Taltz (ixekizumab) has superior efficacy compared to Stelara (ustekinumab). According to Eli Lilly and Co (NYSE:LLY), patients treated for moderate-to-severe plaque psoriasis with the former had better response results at 24 weeks than those who used the latter.

The results included 83% of patients who obtained a Psoriasis Area Severity Index (PASI) score of 90. This was much higher than the 59% of patients who obtained a PASI of 90 after having Stelara administered in them.

Introduction Of Treatments Like Taltz Will Offer More Treatment Options

Taltz could be significant in that it could offer patients who are seeking to achieve PASI 90 or PASI 100 with treatment options. The lead author of the study, Kristian Reich says, “For many years, achieving PASI 75 – or 75 percent improvement in skin plaques – has been the standard treatment goal for moderate-to-severe plaque psoriasis.”

The results of the IXORA-S study, which were presented at the the American Academy of Dermatology (AAD) Annual Meeting, were steady with previous Phase 3 trials. The study involved randomized patients who received either 45 mg or 90 mg of Stelara or 80 mg of Taltz administered very two weeks for 12 weeks and another 80 mg every four weeks.

Adverse Events

There were notable cases of adverse events even though they were not so severe. Taltz, which was endorsed in the U.S., Canadian, and European health agencies almost one year ago, displayed consistency with previous clinical trials in its safety profile.

However, there are precautions to observe. It is likely that the treatment may have a higher risk of infection and severe infections have occurred previously. Hence it is advisable that every user seek guidance from a physician in the event of an acute infection.

Nonetheless, to this point, Eli Lilly and Co (NYSE:LLY)’s global brand development leader, Dr. Lotus Mallbris says that they are happy with the new results because it will enhance the clinical benefits of Taltz. Meanwhile, Eli Lilly and Co (NYSE:LLY)’s stock closed at $82.74 on Tuesday after a decline of 1.09 or 1.30%.

Follow Lilly Eli & Co (NYSE:LLY)
Trade (NYSE:LLY) Now!

Note: This article is written by Adam Russell and was originally published at Market Exclusive.